CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Dupilumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03359356
NCT03359356Phase 2Completed

Defining Reversal of Alopecia Areata (AA) Phenotype With Dupilumab in Patients With and Without Associated Atopic Dermatitis (AD)

Icahn School of Medicine at Mount Sinai·interventional·Posted Dec 2, 2017·Updated Sep 13, 2022

In Brief

A Phase 2 clinical trial evaluating Dupilumab and Placebo for Alopecia Areata. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing the hair follicles as foreign and attacking them, causing round patches of hair loss. It can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). The scalp is the most commonly affected area, but the beard or any hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in males and females of all ages, and is a highly unpredictable condition that tends to recur. Alopecia areata can cause significant distress to both patients and their families. In this study, the aim is to assess the effects of dupilumab in patients with alopecia areata.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesUnited States

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2, 2017
Enrollment StartJan 9, 2018
Primary CompletionJan 14, 2020
Study CompletionDec 17, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.6 years ago

Interventions

Dupilumabdrug

A total of 24 doses

Placebodrug

A total of 24 doses